NASDAQ:ELOX Eloxx Pharmaceuticals Q3 2026 Earnings Results & Report $12.75 -0.40 (-3.04%) As of 04:00 PM Eastern Eloxx Pharmaceuticals reported Q3 2026 earnings on November 13, 2026. The company reported EPS of -$0.49. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 13, 2026TimeBefore Market OpensConference Call DateNovember 16, 2026Conference Call7:00 AM ET Eloxx Pharmaceuticals EPS ResultsActual EPS-$0.49Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEloxx Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Eloxx Pharmaceuticals Q3 2026 Earnings FAQ Did Eloxx Pharmaceuticals beat earnings estimates for Q3 2026? Eloxx Pharmaceuticals (NASDAQ:ELOX) reported earnings of -$0.49 per share for Q3 2026. The report was announced on Friday, November 13, 2026. Eloxx Pharmaceuticals Earnings HeadlinesEloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business UpdateNovember 16 at 7:00 AM | prnewswire.comEloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Stock Has Average Price Target of $37.33 According to BrokeragesNovember 12, 2026 | americanbankingnews.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 16 at 1:00 AM | Weiss Ratings (Ad)Eloxx Pharmaceuticals to Present at the 3rd Annual Guggenheim Healthcare Innovation ConferenceNovember 2, 2026 | prnewswire.comEloxx Pharmaceuticals, Inc. Announces FDA Clearance Of Investigational New Drug Application For Exaluren In Nonsense-Mutation Autosomal Dominant Polycystic Kidney DiseaseOctober 31, 2026 | marketscreener.comMEloxx Gains FDA Clearance For Exaluren Phase 2 Trial In Genetic Kidney DiseaseOctober 29, 2026 | rttnews.comSee More Eloxx Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Eloxx Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eloxx Pharmaceuticals and other key companies, straight to your email. Email Address About Eloxx PharmaceuticalsEloxx Pharmaceuticals (NASDAQ:ELOX) was a clinical-stage biopharmaceutical company focused on developing treatments for rare genetic diseases caused by nonsense mutations. Its research centered on compounds intended to help cells produce functional proteins when a genetic mutation prematurely stops protein production. The company’s lead investigational candidate, ELX-02, was designed to promote ribosomal readthrough of these premature stop signals. Eloxx studied the candidate for conditions including cystic fibrosis and nephropathic cystinosis in patients with relevant genetic mutations. ELX-02 was investigational and was not a marketed treatment. In 2024, Eloxx completed a business combination with Zenas BioPharma, and the combined company began operating under the Zenas BioPharma name.View Eloxx Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/133 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCould Big Buybacks Be the Next Catalyst for These 3 AI Stocks?Cerebras Q3 Results: How Much More Proof Does Wall Street Need? Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.